3 results
The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…
To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…
Primary objectives:# To evaluate the safety of the combination of JNJ-63723283 with apalutamide.# To define a population of subjects with metastatic CRPC who respond to treatment with the combination of JNJ-63723283 and apalutamide.Secondary…